Molegro Virtual Docker-Based Prediction of Rhodomyrtus tomentosa Metabolites Targeting Ribonucleotide Reductase as Potential Anticancer Agents
Abstract
The increasing number of cancer cases has prompted the search for new drug candidates from natural ingredients, particularly plant-derived compounds considered safer and more effective. Rhodomyrtus tomentosa (Aiton) Hassk. contains various metabolites responsible for various biological activities. This study aimed to predict the anticancer potential of R. tomentosa metabolites against the Ribonucleotide Reductase (RNR) enzyme using an in silico approach. The RNR protein structure (PDB ID: 2WGH) was obtained from the RCSB Protein Data Bank. Molecular docking was performed on 25 compounds previously reported in the literature as metabolites of R. tomentosa using Molegro Virtual Docker (MVD) version 7.0 to evaluate ligand-receptor binding affinity based on MolDock Score values using a validated docking protocol (RMSD≤2.0 Å), followed by interaction analysis and pharmacokinetic evaluation using ADMET parameters. The results indicated that most compounds exhibited favorable binding affinities toward RNR, as reflected by negative MolDock Score values. Rhodomyrtosone B (−137.144 kcal/ mol) showed the best binding affinity, followed by Malvidin-3-glucoside (−135.173 kcal/ mol), Delphinidin-3-galactoside (-132.359 kcal/mol), Rhodomyrtosone I (−130.004 kcal/ mol), and Cyanidin-3-galactoside (-127.741 kcal/mol). Interaction analysis revealed stable interactions with key amino acid residues (Arg256, Asp226, and Ser269) through hydrogen bonding, hydrophobic, and electrostatic interactions. ADMET analysis indicated variability in pharmacokinetic properties, including absorption, distribution, metabolism, and toxicity. In conclusion, Rhodomyrtosone B has potential as a natural product-based anticancer agent targeting RNR, providing a basis for further in vitro and in vivo studies.
Keywords: anticancer, Rhodomyrtus tomentosa, molecular docking, Ribonucleotide Reductase; in silico.
Full Text:
PDFReferences
Chen, D., Xu, F., Zhang, P., Deng, J., Sun, H., Wen, X., and Liu, J., 2017, Practical synthesis of a-Amyrin, b-Amyrin, and lupeol: The potential natural inhibitors of human oxidosqualene cyclase, ARCH PHARM Archiv Der Pharmazie, 350(12), 1–9.
Chen, G., Luo, Y., Warncke, K., Sun, Y., Yu, D.S., Fu, H., et al., 2019, Acetylation regulates ribonucleotide reductase activity and cancer cell growth, Nature Communications, 10(1), 3213.
Dachriyanus, Fahmi, R., Sargent, M.V., Skelton, B.W. and White, A.H., 2004, 5-Hy¬droxy-3,3000,4000,5000,7-pentamethoxyfla¬vone (combretol), Acta Crystallographica, 60(1), 86–88.
Fairman, J.W., Wijerathna, S.R., Ahmad, M.F., Xu, H., Nakano, R., Jha, S., et al., 2011, Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization, Nature Structural and Molecular Biology, 18(3), 316–322.
Ferlay, J., Rebecca, M.E. and Mph, L.S., 2024, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, International Agency for Research on Cancer/World Health Organization, 74(3), 229–263.
Fu, L., Shi, S., Yi, J., Wang, N., He, Y., Wu, Z., et al., 2024, ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support, Nucleic Acid Research, 52(W1), W422-W431.
Fujiati, F., Haryati, H., Joharman, J., and Utami, S.W., 2022, In vitro metabolite profiling and anti-inflammatory activities of Rhodomyrtus tomentosa with red blood cell membrane stabilization methods, Reports of Biochemistry & Molecular Biology, 11(3), 503–510.
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., et al., 2025, Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer, Molecular Biomedicine, 6(1), 2.
Hadi, S. and Nastiti, K., 2023, Activity predication of Rhodomyrtus tomentosa (Aiton) Hassk against ACE1 inhibitors, Science Midwifery, 11(2), 348– 355.
Huff, S.E., Winter, J.M., and Dealwis, C.G., 2022, Inhibitors of the cancer target ribonucleotide reductase, past and present, Biomolecules, 12(6), 815.
Idris, M., Purnomo, A.S., Martak, F., Kim, Y-U., and Fatmawati, S., 2023, Chemical compounds and pharmaceutical properties of Rhodomyrtus to mentosa: A traditional medicinal herb from South Kalimantan, Indonesia, Journal of Hunan University Natural Sciences, 50(8), 100–123.
Idris, M., Sukandar, E.R., Purnomo, A.S., Martak, F. and Fatmawati, S., 2022, Antidiabetic, cytotoxic and antioxidant activities of Rhodomyrtus tomentosa leaf extracts, RSC Advances, 12(39), 25697–25710.
Islam, M.O., Bacchetti, T., and Ferretti, G., 2019, Alterations of antioxidant enzymes and biomarkers of nitro-oxidative stress in tissues of bladder cancer, Hindawi Oxidative Medicine and Cellular Longevity, 2019, 2730896.
Jung, K-W., Kwon, S., Jung, J-H., and Bahn, Y-S., 2022, Essential roles of ribonucleotide reductases under DNA damage and replication stresses in Cryptococcus neoformans, Microbiology Spectrum, 10(4), e0104422.
Kesuma, D., Yuniarta, T.A., Putra, G.S., Sumari, S., Sulistyowaty, M.I., and Anwari, F., 2022, In silico, synthesis, structure elucidation and anticancer activity study of 2-(3,4-dichlo¬rophenyl)-4H-benzo[d][1,3]oxazin-4-one, Pakistan Journal of Pharmaceutical Sciences, 35(5), 1391–1398.
Khan, S.U., Fatima, K., Aisha, S., and Malik, F., 2024, Unveiling the mechanisms and challenges of cancer drug resistance, Cell Communication and Signaling, 22, 109.
Lai, H., Wang, L., Qian, R., Huang, J., Zhou, P., Ye, G., et al., 2024, Interformer: an interaction-aware model for protein-ligand docking and affinity prediction, Nature Communications, 15, 10223.
Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J., 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Advanced Drug Delivery Reviews, 46(1-3), 3-26.
Liu, B., Zhou, H., Tan, L., Siu, K.T.H., and Guan, X.-Y., 2024, Exploring treatment options in cancer: Tumor treatment strategies, Signal Transduction and Targeted Therapy, 9(1), 175.
Marwati, M., Alam, G., Yulianty, R., Sami, F.J., Nur, S., Nursamsiar, and Rifai, Y., 2025, In silico evaluation of the glioma activity of reported compounds from the extract Rhodomyrtus tomentosa (Aiton) Hassk., Jurnal Penelitian Pendidikan IPA, 11(6), 215–226.
Nivatya, H.K., Singh, A., Kumar, N., Sonam, Sharma, L., Singh, V., et al., 2025, Assessing molecular docking tools: Understanding drug discovery and design, Future Journal of Pharmaceutical Sciences, 11, 111.
Oktaviyanti, N.D., Budiono, R., Fitriani, E.W., and Avanti, C., 2024, Optimization ultrasound-assisted extraction using choline chloride-based natural deep eutectic solvent to increase phenolic compounds and antioxidants from Rhodomyrtus tomentosa leaves, International Journal of Applied Pharmaceutics, 16(5), 83–90.
Pagadala, N.S., Syed, K. and Tuszynski, J., 2017, Software for molecular docking: A review, Biophysical Reviews, 9(2), 91–102.
Paggi, J.M., Pandit, A., and Dror, R.O., 2024, The art and science of molecular docking, Annual Review of Biochemistry, 93, 389–410.
Pesaresi, A., 2023, Mixed and non-competitive enzyme inhibition: underlying mechanisms and mechanistic irrelevance of the formal two-site model, Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1), 2245168.
Sarmoko, Suprahman, N.Y., Putri, R.A., Zammi, A., Hakim, A.Z.A., Cahyadi, D.R., and Saputra, M.Y., 2025, In silico analysis of Cucurbitacin IIa and Cucurbitacin IIb as potential modulators of oxidative stress regulatory proteins, Indonesian Journal of Cancer Chemoprevention, 15(3), 224–236.
Shahidi, F. and Dissanayaka, C.S., 2023, Phenolic-protein interactions: insight from in-silico analyses a review, Food Production, Processing and Nutrition, 5, 2.
Tayeh, M. and Watanapokasin, R., 2020, Antimetastatic potential of rhodomyrtone on human chondrosarcoma SW1353 cells, Evidence-Based Complementary and Alternative Medicine, 2020, 8180261.
Thomsen, R. and Christensen, M.H., 2006, MolDock: A New Technique for High-Accuracy Molecular Docking, Journal of Medicinal Chemistry, 49(11), 3315-3321.
Vittorio, S., Lunghini, F., Morerio, P., Gadioli, D., Orlandini, S., Silva, P., et al., 2024, Addressing docking pose selection with structure-based deep learning: Recent advances, challenges and opportunities, Computational and Structural Biotechnology Journal, 23, 2141–2151.
Vo, T.S. and Ngo, D.H., 2019, The health beneficial properties of Rhodomyrtus tomentosa as potential functional food, Biomolecules, 9(2), 76.
Winter, R.C., Amghar, M., Wacker, A.S., Bakos, G., Taş, H., Roscher, M., et al., 2024, Future treatment strategies for cancer patients combining targeted alpha therapy with pillars of cancer treatment: External beam radiation therapy, checkpoint inhibition immunotherapy, cytostatic chemotherapy, and brachytherapy, Pharmaceuricals (Basel, Switzerland), 1(8), 1031.
Yuniarta, T.A., Kesuma, D., and Putra, P.P., 2025, Virtual Screening, ADMET Evaluation, and Molecular Docking Approach in the Discovery of Novel Potential Sweetening Agent, MPI (Media Pharmaceutica Indonesiana), 7(2), 124-137.
Zhuang, L., Chen, L.-F., Zhang, Y.-B., Liu, Z., Xiao, X.-H., Tang, W., et al., 2017, Watsonianone A from Rhodomyrtus tomentosa fruit attenuates respiratory-syncytial-virus-induced inflammation in vitro, Journal of Agricultural and Food Chemistry, 65(17), 3481–3489.
DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev16iss2pp107-122
Copyright (c) 2025 Indonesian Journal of Cancer Chemoprevention
Indexed by:
Indonesian Society for Cancer Chemoprevention
